The global response to the DRC Ebola outbreak is finally mobilizing with urgency — the U.S. has committed over $500 million, the U.N. has deployed additional staff and funding, and WHO experts have greenlit a Phase 3 trial of the Ervebo vaccine that could offer cross-protection against the Bundibugyo strain. The Gavi-funded stockpile also has 500,000 doses ready. The trajectory is grim, but current tools, funding and scientific momentum offer a genuine chance to turn this around.
The DRC Ebola outbreak is a catastrophic failure of global preparedness — with a 46% fatality rate, no approved vaccines or treatments, and transmission outpacing response. Bundibugyo Ebola is killing one person every 30 minutes, yet the world dragged its feet as the outbreak has become the country's deadliest. The Ebo-Pep trial — giving frontline health workers a 50% chance of receiving a placebo — only deepens the scandal of how badly responders have been let down.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.11.1